BS_6H1C1ME9
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- overall_survival_months
- 22.56
- os_event
- false
- age_years
- 5.129
- sex
- M
- race
- White
- e1_e2
- E2
- umap1_2d
- -5.353740659
- umap2_2d
- 0.412120316
- umap1_3d
- -0.521292186
- umap2_3d
- 1.889930935
- umap3_3d
- 0.567331937
- dataset
- EPN-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.600
- INFLAMMATORY_RESPONSE+0.520
- ANGIOGENESIS+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- HYPOXIA+0.490
- IL6_JAK_STAT3_SIGNALING+0.480
- COAGULATION+0.420
- ALLOGRAFT_REJECTION+0.410
- INTERFERON_GAMMA_RESPONSE+0.360
- COMPLEMENT+0.350
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.550
- NOTCH_SIGNALING-0.440
- DNA_REPAIR-0.420
- E2F_TARGETS-0.410
- G2M_CHECKPOINT-0.320
- MYC_TARGETS_V1-0.320
- ADIPOGENESIS-0.290
- MITOTIC_SPINDLE-0.220
- BILE_ACID_METABOLISM-0.190
- FATTY_ACID_METABOLISM-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_PJPGVD62 | EPN | EPN Tumor | 0.929 |
| 2 | BS_JRYJGYC4 | high-grade glioma | — | 0.919 |
| 3 | BS_6H1C1ME9 | Posterior Fossa Ependymoma | — | 0.913 |
| 4 | BS_PJPGVD62 | Ependymoma NOS | — | 0.901 |
| 5 | s_150324_1a | EPN | Posterior Fossa EPN | 0.897 |
| 6 | SRR601755 | GTEX | — | 0.896 |
| 7 | X41226e40.d143.43b1.ac92.023809990077 | — | cohortA1 | 0.893 |
| 8 | SJEPD001506_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.888 |
| 9 | SJEPD038_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.878 |
| 10 | SRR1383018 | GTEX | — | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.600 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.520 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.490 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| HYPOXIA | 0.490 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.480 | Inavolisib | — uncovered |
| COAGULATION | 0.420 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.220 | Inavolisib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.210 | Inavolisib | — uncovered |